Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects
Authors:
Open Access
- 26 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (4) , 780-783
Abstract
The aim of this study was to assess the steady-state pharmacokinetic parameters of telavancin, an investigational bactericidal lipoglycopeptide, after intravenous (iv) administration to healthy male and female subjects. In a randomized, double-blind, parallel-group, gender-stratified, two-dose study, 79 adult subjects received three daily 60 min iv infusions of telavancin at 7.5 mg/kg (n = 40) or 15 mg/kg (n = 39). Blood and urine samples were collected for pharmacokinetic analyses at admission, on day 3 pre-infusion and up to 48 h after the start of the day 3 infusion for 73 subjects (45 males and 28 females). Pharmacokinetic parameters were estimated by non-compartmental analysis. Following the day 3 telavancin dose (7.5 or 15 mg/kg), dose-proportional increases in mean peak plasma concentrations (Cmax, 88 versus 186 mg/L for low and high doses, respectively) and total systemic exposures (AUC0–24, 599 versus 1282 mg·h/L for low and high doses, respectively) were observed. Trough concentrations at steady state were 6 mg/L at 7.5 mg/kg/day and 16 mg/L at 15 mg/kg/day. The elimination half-life was dose-independent; the mean ± SD ranged from 6.0 ± 0.6 to 7.5 ± 1.3 h for low and high doses, respectively. Approximately two-thirds of the total telavancin dose was excreted unchanged in urine over 48 h. Pharmacokinetic parameters were similar in males and females. Telavancin displayed linear plasma pharmacokinetics over the dose range 7.5–15 mg/kg/day and was primarily cleared via urinary excretion. No gender-related differences in the pharmacokinetic disposition of telavancin were observed. These data further characterize the pharmacokinetic profile of telavancin, a once-daily therapy targeted for the treatment of serious Gram-positive infections.Keywords
This publication has 8 references indexed in Scilit:
- Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 2006
- Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 StudyAntimicrobial Agents and Chemotherapy, 2006
- Telavancin: in vitro activity against staphylococci in a biofilm modelJournal of Antimicrobial Chemotherapy, 2005
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005
- Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2004
- Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 2004
- In Vitro Activity of TD-6424 againstStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003